Combination treatment for depression and anxiety
CA 2356797 A1 · Owner: Sobolov-Jaynes, Susan Beth · Inventors: Sobolov-Jaynes, Susan Beth; Schmidt, Christopher Joseph
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of treating depression or anxiety in a, mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor, antagonist (e.g. a substance P receptor antagonist) in combination with a 5HT1D receptor, antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically, acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT1D receptor antagonist.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 4, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.